8‑Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors

A series of 2,3,4,4a,10,10a-hexahydropyrano[3,2-b]chromene analogs was developed that demonstrated high selectivity (>2000-fold) for BACE1 vs Cathepsin D (CatD). Three different Asp-binding moieties were examined: spirocyclic acyl guanidines, aminooxazolines, and aminothiazolines in order to modu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2014-12, Vol.57 (23), p.10112-10129
Hauptverfasser: Thomas, Allen A, Hunt, Kevin W, Newhouse, Brad, Watts, Ryan J, Liu, Xingrong, Vigers, Guy, Smith, Darin, Rhodes, Susan P, Brown, Karin D, Otten, Jennifer N, Burkard, Michael, Cox, April A, Geck Do, Mary K, Dutcher, Darrin, Rana, Sumeet, DeLisle, Robert K, Regal, Kelly, Wright, Albion D, Groneberg, Robert, Liao, Jiangpeng, Scearce-Levie, Kimberly, Siu, Michael, Purkey, Hans E, Lyssikatos, Joseph P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A series of 2,3,4,4a,10,10a-hexahydropyrano[3,2-b]chromene analogs was developed that demonstrated high selectivity (>2000-fold) for BACE1 vs Cathepsin D (CatD). Three different Asp-binding moieties were examined: spirocyclic acyl guanidines, aminooxazolines, and aminothiazolines in order to modulate potency, selectivity, efflux, and permeability. Guided by structure based design, changes to P2′ and P3 moieties were explored. A conformationally restricted P2′ methyl group provided inhibitors with excellent cell potency (37–137 nM) and selectivity (435 to >2000-fold) for BACE1 vs CatD. These efforts lead to compound 59, which demonstrated a 69% reduction in rat CSF Aβ1–40 at 60 mg/kg (PO).
ISSN:0022-2623
1520-4804
DOI:10.1021/jm5015132